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Cardiovascular risk is increased in GH deficiency (GHD).
GHD adults are frequently abdominally obese and display
features of the metabolic syndrome. Otherwise healthy ab-
dominally obese subjects have low GH levels and show fea-
tures of the metabolic syndrome as well. We investigated in
healthy nonobese males the effect of the GH receptor antag-
onist pegvisomant in different metabolic conditions. This is a
model for acute GHD without the alterations in body compo-
sition associated with GHD. We compared the effect of pegvi-
somant with that of placebo before and after 3 d of fasting. In
addition, we investigated the effect of pegvisomant under nor-
mal, i.e. fed, conditions.
Three days of fasting as well as pegvisomant alone de-
creased serum free IGF-I levels (1.0 0.15 vs. 0.31 0.05 ng/ml
and 0.86  0.23 vs. 0.46  0.23 ng/ml, respectively). Fasting in
combination with pegvisomant also decreased serum free
IGF-I levels (1.0  0.15 vs. 0.31  0.07 ng/ml). Treatment with
pegvisomant had no additional influence on the decline of free
IGF-I induced by fasting. Pegvisomant alone had no influence
on insulin sensitivity. The increase in insulin sensitivity in-
duced by fasting was comparable to the increase in insulin
sensitivity induced by fasting combined with pegvisomant.
Among serum lipid concentrations, only serum triglycerides
increased significantly as a result of pegvisomant alone (1.0
0.2 vs. 1.6  0.4 mmol/liter). The changes in lipid concentra-
tions induced by fasting alone or pegvisomant were not dif-
ferent from those induced by pegvisomant alone. von Wille-
brand factor antigen levels declined significantly under the
influence of pegvisomant alone (1.1  0.07 vs. 0.8  0.06 U/ml).
In conclusion, in different metabolic conditions the GH re-
ceptor antagonist pegvisomant induces no significant acute
changes in the major risk markers for cardiovascular disease.
These data suggest that the secondary metabolic changes, e.g.
abdominal obesity or inflammatory factors, that develop as a
result of long-standing GHD are of primary importance in the
pathogenesis of atherosclerosis in patients with GHD. (J Clin
Endocrinol Metab 86: 5165–5171, 2001)
ADULTS WITH GH deficiency (GHD) have an increasedrisk for cardiovascular disease (CVD) (1). Four rele-
vant cohort studies investigating 1197 patients receiving rou-
tine replacement therapy without GH have reported a de-
crease in life expectancy of patients with hypopituitarism
(2–5). The overall relative risk for CVD has been estimated
at 1.47 (95% confidence interval, 1.27–1.70) (6). Compared
with age- and sex-matched normal subjects, patients with
GHD have reduced insulin sensitivity, proatherogenic he-
mostasis parameters, and higher serum lipid concentrations.
They thus display characteristic features of the metabolic
syndrome (7, 8). As central adiposity is present in GHD and
because adiposity itself is associated with low GH levels, it
has been postulated that low GH levels play a role in the
metabolic alterations associated with the metabolic syn-
drome (7, 9–11).
GH acts by binding to receptors on liver and other cells.
One GH molecule binds to two receptor molecules on the
target cell, initiating dimerization of these receptor molecules
and finally resulting in the secretion of IGF-I (12, 13). Pegvi-
somant is a genetically manipulated GH molecule that dis-
ables functional dimerization of the two GH receptor mol-
ecules (14, 15). In normal subjects and in patients with
acromegaly, pegvisomant is an effective blocker of GH action
and significantly decreases IGF-I concentrations (16, 17).
The aim of the present study was to investigate whether
GH receptor blockade, as a model of GHD but without the
typical alterations in body composition, influences insulin
sensitivity, hemostasis parameters, and serum lipid concen-
trations in healthy nonobese males. Because fasting has
marked effects on the GH-IGF-I axis, we performed two
studies: 1) a double blind, placebo-controlled, cross-over
study comparing the effects of fasting on insulin sensitivity,
hemostasis parameters, and serum lipid concentrations with
and without pegvisomant; and 2) a single arm study inves-
tigating the effect of pegvisomant during normal (fed)
conditions.
Subjects and Methods
Study subjects
Ten healthy male subjects (mean sd age, 23.4 2.7 yr; range, 20–28)
with a normal body weight (mean  sd body mass index, 21.8  1.8
kg/m2; range, 19.7–25.8) were asked to participate. None of the subjects
had a relevant medical history or used medication. All 10 subjects
participated in the cross-over study, and 5 participated in the single arm
Abbreviations: CV, Coefficient of variation; CVD, cardiovascular dis-
ease; FVIII:c, factor VIII activity; GHD, GH deficiency; HDL, high den-
sity lipoprotein; HOMA, homeostatic model assessment; LDL, low den-
sity lipoprotein; Lp(a), lipoprotein(a); PAI-I, plasminogen activator
inhibitor I; t-PA, tissue plasminogen activator; vWF:ag, von Willebrand
factor antigen; vWF:Cba, vWF collagen-binding activity; vWF:Rco, vWF
ristocetin cofactor.
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study. The local ethical committee approved the study, and all subjects
gave written informed consent.
Experimental design
The study consisted of two parts (Fig. 1). The first part was a double
blind, placebo-controlled, cross-over study comparing GHR blockade
with placebo before and after 3 d of fasting. After an overnight fast
subjects were admitted to the Clinical Research Unit on d 1 at 0730 h.
Blood was drawn at 0800 h, and at 1800 h a single dose of 80 mg
pegvisomant (Sensus Drug Development Corp., Austin, TX) or placebo
was administered sc (Fig. 2). From midnight until the end of the study
(on d 4 at 2000 h), subjects fasted (while having free access to noncaloric
fluids). Each morning at 0800 h blood was drawn. Between the study
periods there was a wash-out period of 3–7 wk.
The second part of the study was a single arm, open label study in
which the effect of GHR blockade under nonfasted conditions (subjects
received a standardized diet) was investigated. After an overnight fast
subjects were admitted to the Clinical Research Unit on d 1 at 0730 h,
at 0800 h blood was drawn, and at 1800 h a single dose of 80 mg
pegvisomant was administered sc. After an overnight fast, blood was
drawn each morning at 0800 h. In this study a detailed analysis of
hemostasis was performed. Hemostasis was assessed on d 1 and 4 at
0800 h.
GH, total IGF-I, free IGF-I, glucose, insulin, total cholesterol, low
density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL)
cholesterol, triglycerides, and lipoprotein(a) [Lp(a)] were determined
from all blood samples. In the single arm study, fibrinogen, plasmino-
gen, antiplasmin, factor VIII activity (FVIII:c), von Willebrand factor
antigen (vWF:ag), vWF ristocetin cofactor (vWF:Rco) activity, vWF col-
lagen-binding activity (vWF:Cba), plasminogen activator inhibitor-I
(PAI-I) antigen, PAI-I activity, tissue plasminogen activator (t-PA) ac-
tivity, and t-PA antigen were determined at baseline and on d 4.
Assays
All assays were performed in duplicate. Samples were measured for
endogenous GH in a two-site immunoassay that does not cross-react
with pegvisomant. The assay exhibits a lower detection limit of 0.02
g/liter GH, an upper end of the working range of 50 g/liter for 25-l
serum samples, and no cross-reaction with pegvisomant up to a con-
centration of 50,000 g/liter (16). The interassay coefficients of variation
(CVs) are 4.1% at 4.0g/liter and 3.8% at 20g/liter. The intraassay CVs
are 3.4% at 0.25 g/liter, 1.9% at 2.5 g/liter, and 4.5% at 25 g/liter
(Med Klinik Innenstadt, Munich, Germany). Serum IGF-I was deter-
mined with a commercially available RIA (Biosource Technologies, Inc.,
Nivelles, Belgium; intra- and interassay CVs, 5.0% and 9.6%, respec-
tively), and free IGF-I was determined with a commercially available
immunoradiometric assay (Diagnostics Systems Laboratories, Inc., Web-
ster, TX; intra- and interassay CVs, 10.3% and 10.7%, respectively).
Glucose was assessed with an automatic hexokinase method (Roche,
Almere, The Netherlands). Insulin was assessed by RIA (Medgenix
Diagnostics, Brussels, Belgium; intra- and interassay CVs, 13.7% and
8.0%, respectively). Total cholesterol, LDL cholesterol, HDL cholesterol,
and triglycerides were assessed with an enzymatic colorimetric test
(Roche Diagnostics, Mannheim, Germany). Lp(a) was assessed by RIA
(Mercodia AB, Uppsala, Sweden).
Blood for determination of hemostasis parameters was obtained by
venipuncture under standardized conditions (overnight fasting, after
15-min rest, no tourniquet use) and collected in citrate (final concen-
tration, 0.105 m), in Stabilyte (Biopool, Umea, Sweden) for determination
of t-PA and PAI-I activities, and in citric acid, theophylline, adenosine,
dipyridamole (Becton Dickinson, Plymouth, UK) for determination of
PAI-I and t-PA antigens. Plasma was obtained by centrifugation at
2000 g for 20 min at 4 C and was stored at80 C until use. FVIII:c was
measured by a one-stage clotting assay. vWF:ag was measured by
ELISA, using rabbit antihuman vWF (DAKO Corp., Glostrop, Denmark)
as the primary antibody and a horseradish peroxidase-conjugated an-
tibody as the secondary antibody. vWF:Rco was assayed with formalin-
fixed platelets using the PAP-4 aggregometer (BioData). vWF:Cba was
assessed by measuring the amount of plasma vWF that binds to collagen
by EIA. Fibrinogen was measured using the Clauss method. PAI-1
activity was measured using the Chromolize PAI-1 bioimmunoassay
(Biopool). t-PA activity was determined using a biofunctional immu-
nosorbent assay (Chromolize, Biopool). PAI-1 antigen and t-PA antigen
were measured using a TintElize PAI-1 and t-PA ELISA, also obtained
from Biopool. Plasminogen and antiplasmin were determined using
chromogenic substrates, S-2251 and S-2403, respectively, on an auto-
mated analyzer (Sysmex, Dade Behring, Marburg, Germany).
Homeostatic model assessment (HOMA)
-Cell function and insulin sensitivity were analyzed with the HOMA
model (provided by Dr. Jonathan Levy, Diabetes Research Laboratories,
Oxford, UK). This is a structural model of glucose-insulin interaction
that describes the functioning of the major effector organs. Simultaneous
assessment of the glucose and insulin concentrations after an overnight
fast in each person allows evaluation of the combination of -cell func-
tion and insulin sensitivity. -Cell function and insulin sensitivity are
expressed in relation to values in a “standard individual,” in which they
are each accorded the value 100%. The HOMA model has been validated
previously (18–21).
Assessment of body composition
Body composition was assessed with bioelectrical impedance assess-
ment (Holtain Ltd., Croswell, UK). Total body resistance was measured
with a four-terminal portable impedance analyzer. Measurements were
made while the subjects lay comfortably on a bed with limbs abducted
from the body. Current injector electrodes were placed just below the
metacarpo-phalangeal/metacarpo-tarsal joint on the dorsal side of the
right hand/foot. Detector electrodes were placed on the posterior side
of the wrist. Impedance was measured after 800 A at 50-kHz current
was injected. A computer program employing empirically derived for-
mulas was used to calculate total body water, fat-free mass, and fat mass.
This method has been shown to be a reliable and valid approach for the
estimation of human body composition in healthy humans (22).
Statistical analysis
All results are reported as the mean sem. As the maximal effect for
all parameters studied was reached on d 4, all comparisons are reported
as baseline vs. d 4. Because all study periods were exactly the same untilFIG. 1. General study design.
FIG. 2. Overview of the study periods.
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1800 h on d 1 and to minimize intraindividual differences we took the
means of the values of the fasting study periods as baseline values.
Means from baseline and d 4 were compared with the Wilcoxon signed
ranks test. Correlations were calculated with Pearson correlation coef-
ficient. All P values are two-sided, P  0.05 was considered significant.
Analyses were performed using SPSS version 9.0 for windows (SPSS,
Inc., Chicago, IL).
Results
GH and total and free IGF-I
Cross-over study. Fasting nonsignificantly increased GH lev-
els (0.3  0.09 vs. 0.6  0.2 g/liter; Fig. 3A). Three days of
fasting combined with pegvisomant resulted in a significant
increase in GH levels (0.3  0.09 vs. 1.8  0.5 g/liter; P 
0.005). Serum total IGF-I levels did not change (fasting,
204.6 19.2 vs. 214.6 30.8 ng/ml; fasting and pegvisomant,
204.6  19.2 vs. 181.5  32.3 ng/ml; Fig. 3B). Three days of
fasting as well as fasting in combination with pegvisomant
decreased serum free IGF-I levels [1.0  0.15 vs. 0.31  0.05
ng/ml (P  0.005) and 1.0  0.15 vs. 0.31  0.07 ng/ml (P 
0.005), respectively; Fig. 3C]. Treatment with pegvisomant
had no influence on the decline of free IGF-I induced by
fasting.
Single arm study. Pegvisomant alone did not significantly
increase GH levels (0.3  0.2 vs. 0.4  0.1 g/liter; Fig. 3A).
Serum total IGF-I levels did not change (190.7  52.3 vs.
229.2 59.2 ng/ml; Fig. 3B), whereas serum free IGF-I levels
decreased significantly (0.86 0.23 vs. 0.46 0.08 ng/ml; P
0.04; Fig. 3C).
Cross-over study vs. single arm study. Compared with pegvi-
somant alone fasting alone and fasting in combination with
pegvisomant had similar effects on GH, total IGF-I, and free
IGF-I concentrations.
Body composition
Cross-over study. Fat mass did not change (Table 1). Fasting
either with or without pegvisomant resulted in a significant
decrease in fat-free mass and total body water (Table 1). As
the change in fat-free mass was significantly correlated with
the change in total body water (P  0.001 for all study
periods), the change in fat-free mass during fasting was most
likely a result of the expected decline in total body water.
Single arm study. Fat mass, fat-free mass, and total body water
did not change (Table 1).
-Cell function and insulin sensitivity
Cross-over study. -Cell function, as measured with the
HOMA model, remained unchanged (baseline vs. fasting,
139.6  14.0% vs. 125.7  20.6%; baseline vs. fasting and
pegvisomant, 139.6  14.0% vs. 156.0  32.5%; Fig. 4A).
Fasting alone or with pegvisomant resulted in a significant
increase in insulin sensitivity [166.4  47.7% vs. 637.3 
139.1% (P  0.02) and 166.4  47.7% vs. 450.1  96.4% (P 
0.008), respectively; Fig. 4B]. The change in insulin sensitivity
induced by fasting was not different from that induced by
fasting combined with pegvisomant.
Single arm study. -Cell function as measured with the
HOMA model remained unchanged (baseline vs. nonfasting
and pegvisomant, 145.8  25% vs. 166.5  15.2%; Fig. 4A).
Pegvisomant without fasting had no significant effect on
insulin sensitivity (163.3  78.6% vs. 82.2  8.0%; Fig. 4B).
Cross-over study vs. single arm study. The changes in -cell
function and insulin sensitivity induced by fasting alone or
with pegvisomant were not different from those induced by
pegvisomant without fasting.
Hemostasis (single arm study only)
VWF:ag changed significantly under the influence of
pegvisomant alone (Table 2). A similar trend was observed
for FVIII:c (baseline vs. 3 d of fasting, 1.7  0.1 vs. 0.9  0.2
IU/ml; P 0.3) and vWF:activity [baseline vs. 3 d of fasting:
vWF:Rco 1.0  0.09 vs. 0.8  0.1 U/ml (P  0.08); vWF:Cba,
1.1  0.2 vs. 0.9 1.0 U/ml (P  0.2)]. Fibrinolysis param-
eters, including PAI-I and t-PA, did not change during treat-
ment (Table 2).
FIG. 3. Mean values (SEM) of GH (A), total IGF-I (B), and free IGF-I
(C): effects of fasting, fasting with pegvisomant, and pegvisomant
alone. *, P 0.05; **, P 0.01 (compared with baseline, by Wilcoxon
signed rank test).
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Lipids
Cross-over study. Fasting alone or in combination with pegvi-
somant resulted in a significant increase in LDL [2.2 0.2 vs.
2.9  0.3 mmol/liter (P  0.01) and 2.2  0.2 vs. 3.1  0.2
mmol/liter (P 0.005)]; however, total cholesterol levels did
not change (3.9  0.2 vs. 4.4  0.3 mmol/liter and 3.9  0.2
vs. 4.7  0.2 mmol/liter; Fig. 5, A and B). HDL cholesterol
levels decreased as a result of fasting alone (1.2 0.1 vs. 1.0
0.1 mmol/liter). This decrease was statistically significant if
fasting was combined with pegvisomant (1.2  0.1 vs. 1.1 
0.07 mmol/liter; P 0.04; Fig. 5C). As a result of the changes
in total and HDL cholesterol, the total/HDL cholesterol ratio
rose significantly as a result of fasting alone and fasting in
combination with pegvisomant [3.5  0.3 vs. 4.7  0.4 (P 
0.005) and 3.5  0.3 vs. 4.5  0.4 (P  0.005); Fig. 5D].
Triglycerides rose after fasting with pegvisomant (0.8  0.1
vs. 1.1 0.2 mmol/liter; P 0.02), but not after fasting alone
(0.8  0.1 vs. 1.0  0.09 mmol/liter; P  0.1; Fig. 5D). Lp(a)
increased significantly after fasting either without or with
pegvisomant [308.2  153.5 vs. 391.8  170.7 U/liter (P 
0.008) and 308.2  153.5 vs. 359.3  153.0 U/liter (P  0.02),
respectively (Fig. 5F)]. The changes in lipid levels induced by
fasting alone were not significantly different compared with
the changes in lipid levels induced by fasting combined with
pegvisomant.
Single arm study. Total, LDL, and HDL cholesterol levels did
not change (3.9  0.3 vs. 4.2  0.3 mmol/liter, 2.2  0.2 vs.
2.4 0.2 mmol/liter, and 1.1 0.2 vs. 1.0 0.07 mmol/liter,
respectively; Fig. 5, A–C). Pegvisomant alone had no influ-
ence on the total cholesterol/HDL cholesterol ratio (4.0 0.5
vs. 4.5 0.6; Fig. 5D). Lp(a) did not change (567.0 313.5 vs.
599.8  333.7 U/liter; Fig. 5F). The only lipid particle that
changed significantly was triglycerides (1.0 0.2 vs. 1.6 0.4
mmol/liter; P  0.04; Fig. 5E).
Cross-over study vs. single arm study
The changes in lipid concentrations induced by fasting
alone or with pegvisomant were not different from those
induced by pegvisomant without fasting.
Discussion
GHD is associated with central obesity, insulin resistance,
proatherogenic hemostasis parameters, and elevated serum
lipid concentrations (7, 8, 23). Treatment of GHD adults with
GH attenuates central obesity and induces positive effects on
lipid levels (24–27). Because adiposity in otherwise healthy
subjects is associated with low levels of GH, and treatment
of middle-aged obese males with GH resulted in a reduction
of central adiposity with favorable effects on insulin sensi-
tivity and lipid metabolism, several researchers have sug-
gested an important role for GH in the development of cen-
TABLE 1. Mean  SEM body composition values: effects of fasting, fasting with pegvisomant and pegvisonant alone
Baseline
Day 4
Cross-over study Single arm
study: PegVFasting Fasting  PegV
Fat mass (kg) 19.0  2.6 19.3  2.4 18.7  2.1 20.0  3.8
Fat-free mass (kg) 57.0  2.1 53.1  1.9a 53.8  2.0b 57.6  4.0
Total body water (liter) 41.6  1.5 38.7  1.4a 39.2  1.5b 42.1  2.9
All comparisons are pairwise. PegV, Pegvisomant.
a P  0.01, baseline vs. d 4.
b P  0.05, baseline vs. d 4.
FIG. 4. Mean values (SEM) of -cell function (%B; A) and insulin
sensitivity (%S; B): effects of fasting, fasting with pegvisomant, and
pegvisomant alone. *, P 0.05; **, P 0.01 (compared with baseline,
by Wilcoxon signed rank test).
TABLE 2. Mean  SEM coagulation and fibrinolysis parameters:
effects of pegvisomant alone
Baseline Pegvisomant
Fibrinogen (g/liter) 2.3  0.2 2.4  0.3
Plasminogen (IU/mliter) 1.0  0.03 1.0  0.03
Antiplasmin (IU/mliter) 0.9  0.04 1.0  0.08
FVIII:c (IU/mliter) 1.1  0.1 0.9  0.2
VWF:ag (U/mliter) 1.1  0.07 0.8  0.06a
VWF:Cba. (U/mliter) 1.1  0.2 0.9  1.0
VWF:Rco (U/mliter) 1.0  0.09 0.8  0.1
PAI-I activity (IU/mliter) 10.9  3.8 19.9  6.8
PAI-I antigen (ng/mliter) 19.3  6.0 22.2  5.5
t-PA activity (IU/mliter) 0.4  0.2 0.4  0.2
t-PA antigen (ng/mliter) 5.6  0.5 5.9  1.2
FVIII:c, Factor VIII activity; vWF:ag, von Willebrand factor anti-
gen; Cba, collagen-binding activity; Rco, ristocetin cofactor activity;
PAI-I, plasminogen activator inhibitor-I; t-PA, tissue plasminogen
activator.
a P  0.05, baseline vs. d 4.
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tral adiposity and the associated metabolic consequences
(28, 29).
By using the GH receptor antagonist pegvisomant we set
out to study the effects of functional GHD independently
from the eventual alterations in body composition that are
associated with long-standing GHD (7). In our study max-
imal pegvisomant drug levels were achieved on d 4 (fasting
in combination with pegvisomant vs. pegvisomant only,
5228  745.6 vs. 4164  788.3 ng/ml; P  0.45, by Mann-
Whitney U test), these levels were more than 2000-fold higher
than endogenous GH levels. We used free IGF-I as a measure
for assessing the efficacy of the GH receptor blockade (30–
32). Indeed, pegvisomant induced a significant reduction in
free IGF-I resulting in free IGF-I levels on d 4 comparable to
those observed in hypopituitarism with GHD (33). Although
free IGF-I may not be a marker for all local (paracrine and/or
autocrine) GH actions, the observed decline in free IGF-I
levels can be taken to indicate efficient GH receptor blockade
and, as we have to assume, that GH exerts its actions through
the GH receptor. These data, indeed, indicate that the ad-
ministration of pegvisomant creates a state of acute (func-
tional) GHD.
Fat mass was not altered in our study; however, fat-free
mass decreased as a result of fasting. This implies that lean
body mass also decreased. It should be noted that this de-
crease in fat-free mass could be fully accounted for by the
concomitant, metabolically inert decline in total body water.
Pegvisomant alone had no effect on insulin sensitivity, and
although insulin sensitivity increased as a result of fasting,
this increase was not influenced by additional GH receptor
blockade. From these data we conclude that acute impair-
ment of the GH signaling cascade has no immediate effect on
insulin sensitivity. In a recent study Christopher et al. (34)
described a negative correlation between insulin sensitivity
and IGF-I levels. In our study no significant correlations were
observed between changes in free IGF-I and insulin
sensitivity.
The increased risk of cardiovascular disorders in GHD has
been partially ascribed to changes in hemostasis in these
patients, such as an increase in serum fibrinogen concentra-
tion and increased PAI-I activity (8, 35). High fibrinogen
levels are associated with an increased incidence of stroke
and myocardial infarction, and high PAI-I activity or antigen
is an independent risk factor for primary and recurrent myo-
FIG. 5. Mean values (SEM) of total cholesterol (A), LDL cholesterol (B), HDL cholesterol (C), total/HDL cholesterol ratio (D), triglycerides (E),
and Lp(a) (F). *, P  0.05; **, P  0.01 (compared with baseline, by Wilcoxon signed rank test).
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cardial infarction (36–38). Johansson et al. (8) have shown
that GHD adults have higher fibrinogen and PAI-I activity
compared with healthy controls matched for sex, age, and
body mass index. In a subsequent study they observed a
decrease in PAI-I after 2 yr of GH therapy (35). In addition
to GHD, increased PAI-I activity has been found in abdom-
inally obese subjects, and a reduction of PAI-I levels has been
observed after weight loss (39). Probably this is due to a
decrease in insulin resistance as a result of weight loss (40).
So it is unclear whether the observed changes in PAI-I ac-
tivity, PAI-I antigen, and t-PA antigen are due to a direct
effect of GH itself or to changes in body composition. How-
ever, the fact that in our study we observed no significant
changes in PAI-I levels makes a causative role of GH itself in
the elevation of PAI-I observed in GHD less likely.
Interestingly, pegvisomant resulted in a significant de-
crease in vWF.ag, and a similar trend was seen for FVIII and
vWF activity. It has long been recognized that there is a
relationship between GH and vWF. A rise in GH is associated
with increased vWF activity in healthy subjects (41). Our
study thus supports these data. In GHD subjects, Jorgensen
et al. (42) found only a nonsignificant increase in vWF:ag
levels after 4 months of GH replacement therapy in 22 adult
GHD subjects. Johansson et al. (35) investigated the long-term
effects of GH replacement therapy on hemostasis and fibri-
nolysis and found a nonsignificant decrease 24 months after
initiation of GH replacement therapy. However, vWF levels
before the start of GH replacement were not decreased com-
pared with those in normal subjects in this study (35). Besides
vWF, all other hemostatic parameters, including fibrinogen,
plasminogen, antiplasmin, and t-PA, remained unchanged
by pegvisomant administration. Therefore, GH does not
seem to play an important direct role in the regulation of
hemostasis. The changes in coagulation factors observed in
GHD are probably caused by the metabolic changes induced
by long-standing GHD.
Pegvisomant alone increased the serum triglyceride con-
centration, indicating that GH is directly involved in the
regulation of serum triglycerides. However, in a previous
cross-sectional study we observed a strong negative corre-
lation between free IGF-I and triglycerides (43). Moreover,
administration of recombinant IGF-I has been reported to
cause a decrease in triglyceride levels (44). Taken together
these data indicate that GH and IGF-I are both involved in
triglyceride metabolism. Fasting alone, fasting in combina-
tion with pegvisomant, and pegvisomant alone had similar
effects on all of the assessed lipid particles. In accordance
with the previously described data concerning insulin sen-
sitivity and coagulation and fibrinolysis factors, these data
also point to a primary role of changes in body composition
and not of GH itself in the metabolic changes seen in GHD
patients.
Several researchers have reported that GH increases and
IGF-I decreases circulating Lp(a) (45–47). Surprisingly,
pegvisomant induced no change in Lp(a). It could be argued
that the 4-d study period is too short to induce significant
changes. However, 4 d of fasting independently of GH re-
ceptor blockade was able to induce significant changes in
Lp(a). Apparently GH and IGF-I are, at least in the short term,
of only minor importance in the regulation of Lp(a).
In conclusion, in different metabolic conditions the GH
receptor antagonist pegvisomant induces no significant
changes in the major risk markers for CVD. Based on these
data we hypothesize that the secondary metabolic changes,
e.g. abdominal obesity or inflammatory factors (48), that de-
velop as a result of long-standing GHD are of primary im-
portance in the pathogenesis of atherosclerosis in patients
with GHD.
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